Breaking News

Evaxion Biotech A/S Names Per Norlén as CEO

Norlén will succeed Lars Staal Wegner, who has decided to resign.

Author Image

By: Charlie Sternberg

Associate Editor

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has announced several executive management changes.   First, Lars Staal Wegner has decided to resign as the company’s Chief Executive Officer. Wegner will remain with the company in an advisory role to the company’s new CEO and Board of Directors.   In Wegner’s place, the company has appointed Per Norlén, M.D., PhD., a physician and board-certified specialist in Clinical ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters